Review Article

Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Noel Jacques Awi and Sin-Yeang Teow

Department of Medical Sciences (DMS), School of Healthcare and Medical Sciences (SHMS), Sunway University, Jalan Universiti, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia

Correspondence should be addressed to Sin-Yeang Teow; ronaldt@sunway.edu.my

Received 25 January 2018; Revised 10 April 2018; Accepted 26 April 2018; Published 3 June 2018

Academic Editor: Nongnuch Vanittanakom

Copyright © 2018 Noel Jacques Awi and Sin-Yeang Teow. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acquired immunodeficiency syndrome (AIDS) cases are on the rise globally. To date, there is still no effective measure to eradicate the causative agent, human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART) is being used in HIV/AIDS management, but it results in long-term medication and has major drawbacks such as multiple side effects, high cost, and increasing the generation rate of escape mutants. In addition, HAART does not control HIV-related complications, and hence more medications and further management are required. With this, other alternatives are urgently needed. In the past, small-molecule inhibitors have shown potent antiviral effects, and some of them are now being evaluated in clinical trials. The challenges in developing these small molecules for clinical use include the off-target effect, poor stability, and low bioavailability. On the other hand, antibody-mediated therapy has emerged as an important therapeutic modality for anti-HIV therapeutics development. Many antiviral antibodies, namely, broad neutralizing antibodies (bNAbs) against multiple strains of HIV, have shown promising effects in vitro and in animal studies; further studies are ongoing in clinical trials to evaluate their uses in clinical applications. This short review aims to discuss the current development of therapeutic antibodies against HIV and the challenges in adopting them for clinical use.

1. Current HIV Treatments

The discovery of HAART in 1996 has successfully reduced the global mortality rate due to HIV/AIDS [1]. This therapeutic strategy targets multiple viral proteins that are essential for viral replication and dissemination (e.g., envelope protein, reverse transcriptase, integrase, and protease), instead of targeting a single target. This combination therapy could potently suppress the viral load to minimal level. However, the treatment cost is extremely high and this therapy often results in numerous side effects that significantly affect the patients’ life quality [2]. Depending on the conditions, the mild side effects could be weight loss, diarrhoea, anaemia, constipation, dizziness, insomnia, headache, fatigue, rashes, abdominal pain, emotions, nausea, and vomiting, while the potentially fatal complications are liver failure, lipodystrophy, and neurological and cardiovascular diseases [2]. In addition to physical health, other problems in mental and social health have also been reported [2]. It has also been shown that the use of HAART leads to long-term medication of HIV/AIDS patients, and it could introduce multiple drug-resistant escape mutants due to the high mutation rate and recombination frequency of the virus [3]. A large number of drug-resistant HIV variants have been previously reported, and they are known to be resistant to various drug groups such as nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, integrase inhibitors, and entry inhibitors [3]. Hence, other more effective and less toxic alternatives are urgently needed to treat HIV/AIDS. A proper use of anti-HIV drug is also important in order to control the overwhelming number of escape mutants.

In the past, small-molecule inhibitors have demonstrated promising antiviral effects against HIV [4–7]. These inhibitors target various viral proteins such as integrase [8], nucleocapsid [9], capsid [10], and envelope [11] as well as
cellular proteins of target cells such as CD4 [12], kinases
[13], and cellular cofactor [14]. T20 peptide (Enfuvirtide)
is the first HIV entry inhibitor approved by United States
Food and Drug Administration (U. S. FDA) in 2003 [15]
followed by the approval of the first chemokine receptor 5
(CCR5) small-molecule antagonist, Maraviroc (Selzentry) in
2007 [16]. However, these drugs have their limitations in the
clinical applications [6, 17]. Meanwhile, other small-molecule
inhibitors are being evaluated in clinical trials. For instances,
small-molecule NNRTIs, cabotegravir, and rilpivirine were
evaluated in randomised phase 2b trials and the result of the
trial has been recently published [18]. Following Maraviroc,
small-molecule CCR5 antagonists, aplaviroc, and vicriviroc
are currently being evaluated in phase 2b clinical trials for
HIV therapy [19]. A small-molecule ABX464 that inhibits
HIV replication is also expected to enter phase 2b trials in
2018 [20]. Despite the advancement of biological and
chemical engineering technology, it remains a huge challenge
to deliver a safe, stable, and functional molecule into the host
system to completely eradicate the residing virus [6].

Antibody-based therapies possess several advantages
over the chemical-based treatment in various aspects such as
specificity and safety [21]. A number of therapeutic
antibodies have been approved by FDA for cancer therapies
[22]. In the past three years, therapeutic antibodies targeting
programmed death protein 1 (PD-1) and programmed death
ligand 1 (PD-L1) to boost human immune responses against
cancer cells [23] have been approved by FDA to treat various
cancers including melanoma [24], non-small cell lung cancer
(NSCLC) [25], and head and neck squamous cell carcinoma
(HNSCC) [26]. For viral infection prevention and treatment,
several antibodies targeting multiple types of viruses such as
human cytomegalovirus (HCMV), influenza, respiratory
cyncialtivirus(RSV),Ebola,rabies,andHIVarebeingevaluated
in clinical trials [21]. The development of therapeutic
antibodies, in particular, the broad neutralizing antibodies
(bnAbs) against various HIV strains, will be emphasized and
discussed in later sections.

2. Development of HIV-1-Neutralizing
Antibodies against HIV/AIDS

Broad neutralizing antibodies (bnAbs) are neutralizing anti-
bodies that neutralize multiple HIV-1 viral strains by tar-
getting conserved epitopes of virus [60]. BnAbs have shown
promising effects against various HIV strains and have
significantly contributed to HIV vaccine development [60].
The earliest bnAb, b12 were discovered in 1991 [61], and
increasing bnAbs have been seen in recent years [60]. All
of the bnAbs information is freely available on a website
known as broadly neutralizing antibodies electronic resource
(bnAbER) which aims to support the researchers to generate
a potent HIV vaccine [62]. Table 1 shows a list of bnAbs
targeting multiple HIV-1 epitopes in the past 10 years. These
bnAbs were raised from blood of HIV-1 infected patients and
this information is tabulated in Table 1. Generally, anti-HIV
bnAbs can be categorized into two groups: first and second
[63]. Both of these groups differ from the method used for
generation of bnAbs and their functionalities. Examples of
“first-generation” antibodies are b12, 2G12, 4E10, and 2F5.
These bnAbs were developed from Epstein-Barr virus- (EBV-
) immortalized B cells and generated using phage-display
methods [63]. Although these bnAbs resulted in 50%–88%
of neutralization breadth, they are not ideal for antibody-
based vaccine mainly due to the relatively low neutralization
efficacy and limitation of method such as antibody specificity
selection and lack of high throughput screening option
[64]. On the other hand, “second-generation” bnAbs possess
improved neutralization potency and offer high flexibility in
technology manipulation. The advancement of technology
allows the selection of chronically HIV-1-infected “Elite
neutralizers,” new screening and selection method, and new
antibody isolation and analysis method [64]. Examples of
“second-generation” bnAbs are PG9, PG16, CH01, PGT145,
PGT121, PGDM100, 10-1074, 10E8, VRC01, 3BNC117, and
CH103.

To date, none of the FDA-approved therapeutic anti-
bodies are used for HIV treatment. The development of
therapeutic antibodies against HIV is ongoing and many of
them have successfully progressed to human clinical trials
[46, 65]. Table 2 shows the anti-HIV antibodies that are being
evaluated in different phases of trials. HIV-1 envelope protein
is a popular therapeutic target for various antiviral pharma-
ceuticals and vaccine design [66]. Scheid and group demon-
strated the result of phase 2a trial using HIV Env-specific
antibody, 3BNC117 on 13 HIV-infected patients. They showed
that the broad neutralizing antibody (bnAb) 3BNC117 exerted
strong selective pressure on HIV-1 emerging from latent
reservoirs [43]. Similarly, another monoclonal antibody, 10-
1074 targeting V3 glycan site of HIV-1 Env protein, showed
potent effect and high tolerant limit in phase I trial [44]. Bar
and colleagues showed another bnAb, VRC01 to effectively
suppress the plasma viremia below detectable concentration
in phase I trial [45]. The same study also highlighted the
emergence of VRC01-resistant HIV after the exposure as the
main challenge [45]. Other monoclonal antibodies targeting
HIV envelope glycoproteins that are currently under phase I
trials are PGDM1400, PGT121, N6, and 10E8v4 (Table 2)
[46]. Recently, Xu and group generated highly potent trispe-
cific antibodies by combining the specificity of PGDM1400,
VRC01, and 10E8v4 [47]. These engineered antibodies inter-
act with three different sites of envelope protein: membrane-
proximal external region (MPER)-, CD4-, and V1V2-binding
sites. These antibodies conferred a complete immunity by
displaying high breadth and potency against simian-human
immunodeficiency viruses (SHIVs) in nonhuman primates
compared to each parental antibody. This antibody developed
by Sanofi is expected to enter phase I trial in late 2018 [47].

Antibodies that are targeting cellular proteins essential
for HIV replication such as CD4 and coreceptors have
also been shown to efficaciously eradicate the HIV. Some
of these antibodies are undergoing clinical trials. TMB-355
(previously known as TMB-301), also known as ibalizumab,
targets CD4 receptor and prevents the viruses from binding to
them. A phase 3 trial demonstrated that ibalizumab is a safe
and well-tolerated drug and can be used as a monotherapy
especially for multidrug-resistant HIV patients with limited
treatment options [51]. Researchers are currently developing
Table 1: Anti-HIV broad neutralizing antibodies (bnAbs) in the past 10 years.

<table>
<thead>
<tr>
<th>Viral epitope</th>
<th>Name</th>
<th>Year</th>
<th>Sample source</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1V2 glycan site</td>
<td>PG9, PG16</td>
<td>2009</td>
<td>Clade A-infected African</td>
<td>[27]</td>
</tr>
<tr>
<td></td>
<td>CH01</td>
<td>2011</td>
<td>Chronically infected donor (CH0219)</td>
<td>[28]</td>
</tr>
<tr>
<td></td>
<td>PGT145</td>
<td>2011</td>
<td>Chronically infected donor 84</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>PGDM1400</td>
<td>2014</td>
<td>Chronically infected donor 84</td>
<td>[30]</td>
</tr>
<tr>
<td>V3 glycan site</td>
<td>PGT121, PGT125, PGT135</td>
<td>2011</td>
<td>HIV-1 infected donor (at least 3 years)</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>10-1074</td>
<td>2011</td>
<td>Clade A-infected African donor (patient 10)</td>
<td>[31]</td>
</tr>
<tr>
<td>gp41 MPER</td>
<td>2F5</td>
<td>2009</td>
<td>PBMCs from patient SC44</td>
<td>[32]</td>
</tr>
<tr>
<td></td>
<td>4E10</td>
<td>2009</td>
<td>PBMCs from patient SC44</td>
<td>[32]</td>
</tr>
<tr>
<td></td>
<td>HK20</td>
<td>2010</td>
<td>Patients plasma that showed &gt;80% neutralization</td>
<td>[33]</td>
</tr>
<tr>
<td></td>
<td>M66.6</td>
<td>2011</td>
<td>PBMCs from patient SC44</td>
<td>[32]</td>
</tr>
<tr>
<td>CAP206-CH12</td>
<td>PGT121, PGT125, PGT135</td>
<td>2011</td>
<td>HIV-1 infected donor (at least 3 years)</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>10-1074</td>
<td>2011</td>
<td>Clade A-infected African donor (patient 10)</td>
<td>[31]</td>
</tr>
<tr>
<td>CD4 binding site</td>
<td>VRC01</td>
<td>2010</td>
<td>PBMCs from donor 45</td>
<td>[37]</td>
</tr>
<tr>
<td></td>
<td>HJ16</td>
<td>2010</td>
<td>Patients plasma that showed &gt;80% neutralization</td>
<td>[33]</td>
</tr>
<tr>
<td></td>
<td>HGN194</td>
<td>2010</td>
<td>Patients plasma that showed &gt;80% neutralization</td>
<td>[33]</td>
</tr>
<tr>
<td></td>
<td>3BNC117</td>
<td>2011</td>
<td>RU01 B-cell clones from patient donor</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>3BNC55</td>
<td>2011</td>
<td>RU01 B-cell clones from patient donor</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>VRC-CH131</td>
<td>2011</td>
<td>Chronically infected donor (CH0219)</td>
<td>[28]</td>
</tr>
<tr>
<td></td>
<td>NIH45</td>
<td>2011</td>
<td>RU12 B-cell clones from patient donor</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>8ANC195</td>
<td>2011</td>
<td>RU12 B-cell clones from patient donor</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>8ANC131</td>
<td>2011</td>
<td>HIV-1 infected donor RU8</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>12A12</td>
<td>2011</td>
<td>RU16 B-cell clones from patient donor</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>1B2530</td>
<td>2011</td>
<td>HIV-1 infected donor RU1</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>3BC176</td>
<td>2012</td>
<td>HIV-1 infected patient 3B</td>
<td>[40]</td>
</tr>
<tr>
<td></td>
<td>3BC315</td>
<td>2012</td>
<td>HIV-1 infected patient 3B</td>
<td>[40]</td>
</tr>
<tr>
<td></td>
<td>CH103</td>
<td>2013</td>
<td>HIV-1 infected donor CH505</td>
<td>[41]</td>
</tr>
<tr>
<td></td>
<td>N6</td>
<td>2016</td>
<td>HIV-1-infected patient Z258</td>
<td>[42]</td>
</tr>
</tbody>
</table>

Table 2: Therapeutic antibodies that are being evaluated in the clinical trials.

<table>
<thead>
<tr>
<th>Source</th>
<th>Target</th>
<th>Name</th>
<th>Clinical trial</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral</td>
<td>Env CD4 binding site</td>
<td>3BNC117</td>
<td>Phase 2a</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td>Env V3 glycan site</td>
<td>10-1074</td>
<td>Phase I</td>
<td>[44]</td>
</tr>
<tr>
<td></td>
<td>Env CD4 binding site</td>
<td>VRC01</td>
<td>Phase I</td>
<td>[45]</td>
</tr>
<tr>
<td></td>
<td>Env V3 glycan site</td>
<td>PGT121</td>
<td>Phase I</td>
<td>[46]</td>
</tr>
<tr>
<td></td>
<td>Env MPER</td>
<td>10E8v4</td>
<td>Phase I</td>
<td>[47]</td>
</tr>
<tr>
<td></td>
<td>Env CD4 binding site</td>
<td>N6</td>
<td>Phase II</td>
<td>[42]</td>
</tr>
<tr>
<td>Cellular</td>
<td>CCR5</td>
<td>HGS004</td>
<td>Phase I</td>
<td>[48]</td>
</tr>
<tr>
<td></td>
<td>CCR5</td>
<td>PRO140</td>
<td>Phase III</td>
<td>[49]</td>
</tr>
<tr>
<td></td>
<td>CCR5/CCR2</td>
<td>Cenicriviroc</td>
<td>Phase III</td>
<td>[50]</td>
</tr>
<tr>
<td></td>
<td>CD4</td>
<td>TMB-355</td>
<td>Phase III</td>
<td>[51]</td>
</tr>
<tr>
<td></td>
<td>PDL1</td>
<td>BMS-936559</td>
<td>Phase I</td>
<td>[52]</td>
</tr>
</tbody>
</table>

A new formulation of ibalizumab for the intramuscular injection use [51]. Various antibodies targeting chemokine coreceptor 5 (CCR5), such as HGS004, PRO140, and Cenicriviroc (Table 2), have shown promising antiviral effects and are now being evaluated in clinical trials. An anti-PDL1 antibody, BMS-936559 has been evaluated in a phase I trial on HIV patients, and the results showed that the immunologic checkpoint inhibitor could enhance the HIV-specific immunity in a subset of participants in the trial [52]. Apart from the abovementioned antibodies, other anti-HIV therapeutic antibodies are being evaluated and these antibodies have been discussed in several reviews [59, 67–69].
Table 3: Challenges of FDA-approved anti-HIV therapeutic antibodies development.

<table>
<thead>
<tr>
<th>Challenge</th>
<th>Notes</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>Phage-display library is the most commonly used technique for therapeutic antibody generation. The technique allows both genetic and chemical modification of antibody fragments.</td>
<td>[53], [54]</td>
</tr>
<tr>
<td>Cost</td>
<td>The production cost of antibody is higher than the synthesis of small-molecule antivirals. The generation of recombinant antibodies results in higher manufacturing cost.</td>
<td>[21]</td>
</tr>
<tr>
<td>Host immunology</td>
<td>Individuals’ immune responses towards therapeutic antibodies may be different</td>
<td>[55]</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Geographical distribution affects the resistance mechanism and neutralization escape of viral strains</td>
<td>[56]</td>
</tr>
<tr>
<td>Delivery</td>
<td>Conjugation with cell-penetrating peptides improves the cellular delivery of antibodies. Smaller antibody formats such as Fabs, sdAbs, and scFvs also facilitate tissue delivery</td>
<td>[57]</td>
</tr>
<tr>
<td>Stability</td>
<td>Fc region engineering improves the half-life, stability, and the effector function of the antibody</td>
<td>[58]</td>
</tr>
<tr>
<td>Resistant mutants</td>
<td>Development of antibody-resistant HIV mutants has been reported in VRC01-treated patients; combination therapy will minimize the occurrence of virus mutation</td>
<td>[45]</td>
</tr>
<tr>
<td>Toxicity</td>
<td>IL-2 and IFN-y therapy that may be used as adjuvant therapy for bnAbs therapy to stimulate T-cell killing and HIV-1 transcription resulted in high level of cytototoxicity</td>
<td>[59]</td>
</tr>
</tbody>
</table>

These investigational therapeutic antibodies are being evaluated preclinically before entering the human trials.

Compared with other chemical-based or small-molecule treatment, antibody-based treatment offers a more comprehensive targeting and neutralization, and hence a more potent anti-HIV actions. One of the key components of bnAbs is the IgG Fc region. Using humanized mouse models, Halper-Stromberg et al. demonstrated that the HIV suppression by the passively transferred antibodies was dependent on interaction of the IgG Fc with Fc receptors of immune cells [70]. Other studies have also highlighted the Fc receptor-mediated effector functions of bnAbs in HIV inhibition through antibody-dependent cell-mediated cytotoxicity (ADCC) against both free virus and virus-infected cells [71, 72]. Fc domains of antibodies also interacted with natural killer cells and phagocytes for viral particle clearance and killing of virus-infected cells [73]. It is clear that while reactivity and affinity of bnAbs play pivotal roles in determining the antibody neutralization capacity, the Fc-mediated effector mechanisms also play part in the antiviral activities.

### 3. Challenges in Antibody-Based Therapies

As discussed above, antiviral antibodies serve as a highly potential therapeutic modality against HIV. However, there are multiple challenges in the development of these antibodies. These challenges have intensively slowed down the FDA approval of the anti-HIV antibodies into the market. This section discusses the challenges in developing the antibodies into clinical use (summarized in Table 3).

The main challenge of antibody therapy against HIV is the method used for humanized antibody production. Phage-displayed library is the most popular platform used to generate therapeutic human antibodies in the past decade and many of these phage-display-generated antibodies have been approved by FDA or European Medicines Agency (EMA) [53, 74]. This technique enables the construction of antibodies in Fab or scFv fragments and display on filamentous phage. The antibodies are then isolated and enriched by panning against antigen of interest. Due to the relatively lower throughput, phage-display technique has been switched to cell sorting and RT-PCR for antibody isolation. Use of these methods has generated many more bnAbs known as “second-generation” bnAbs. Various sources have been used for the therapeutic antibody production against viruses, including total B cells [75], single memory B cells [21], and single plasma B cells [21].

Several reports have also shown the efficacy of isolating the antibodies from native phage libraries which possess potent neutralization activities against viruses [76]. The downside of this technique is that it cannot be used to identify new neutralizing epitopes of virus [21]. This method has also been described as a time-consuming and laborious approach [77]. Other alternatives to generate the therapeutic antibodies include proteomics-directed cloning of antibodies [78] and deep sequencing of paired antibodies encoding genes [79]. The development of antibody generation technique is also highly associated with the production cost. The advancement of technologies allows the production of recombinant antibodies with improved therapeutic effects as well as other refined properties including tissue delivery and stability. For instance, antibody in single-domain antibodies (sdAbs) format allows an efficient target binding and fast tissue penetration compared to the conventional full-length antibodies; this may enhance the antiviral activities [80]. However, this strategy needs to be reconsidered as cumulative evidences have shown the importance of Fc region of Abs in antiviral action; antibodies without Fc region would significantly reduce the overall neutralizing activities [70–72]. To improve the stability and biodistribution of therapeutic full-length antibodies and the effector functions, Fc region engineering plays an important role in improving the antibody clinical efficacy [81, 82]. Antibody-based therapies are generally well-tolerated and safe; however, this can be further improved by antibody engineering as previously described [83]. While antibody engineering is speculated to benefit the future of HIV/AIDS therapy, these modifications will increase the production cost compared to the standardized manufacturing.
protocol as well as the synthesis of antiviral small molecules. The production cost is the key factor for anti-HIV antibody therapy due to the smaller market in viral diseases compared to cancer diseases [21]. There is also a rising concern following the increasing number of FDA-approved small-molecule inhibitors for HIV/AIDS therapy [10, 13, 18, 20]. Although the antibody- and molecule-based therapeutics have different antiviral mechanisms, the comparison and competition between the antiviral antibodies and the substantial number of small-molecule inhibitors in the market is unavoidable. Another challenge of developing therapeutic antibodies is the biological variation from host to host. Certain population of HIV-infected patients may not respond to a particular antibody or is suitable even though it has been proven efficacious and safe in a group of patients who have differences in terms of individuals’ immunology, vaccination, diet, lifestyle, and geographical factors [21]. The treatment failure is also highly related to the biology of target virus including the mechanism of infection, mutation rate, and neutralization escape [84]. Other key challenges are the delivery and stability of antibodies for HIV therapies (Table 2). As tabulated in Table 1, all of the drug targets are viral and cellular proteins or receptors. Recent reports have highlighted the potential of targeting intracellular proteins using therapeutic antibodies for the development of HIV/AIDS therapies [85, 86]. However, conventional antibodies do not penetrate into the cells and target intracellular proteins [87]. To solve this problem, conventional antibodies can be conjugated with cell penetrating peptides (CPPs) derived from various sources to enter the cell cytoplasm [88]. Antibodies in smaller format such as Fabs, scFvs, and sdAbs (with Fc removal) have also been constructed for this purpose [57, 89, 90]. These antibodies have targeted various intracellular proteins including capsid [91], integrase [92], and other accessory proteins such as Nef [93], Vif [94], Tat [95], and Rev [96]. The clinical application of these intracellular-targeting antibodies remains to be seen.

Compared to other therapeutic modalities such as HAART and other small-molecule inhibitors, antiviral bnAbs are active against multiple types of HIV strains at low doses with acceptable toxicities [97]. For example, 3BNC117 could prevent mucosal transmission in high-dose challenge in humanized mouse models at low doses [98]. On the other hand, combination of NIH45-46m2, 10-1074, and 10E8 resulted in 100% neutralization of HIV-1 variants at a low concentration (IC50 of ≤0.37 μg/mL) compared to the individual bnAb alone [99]. Although the toxicity of anti-HIV bnAbs therapy is less reported, it has been reported in other adjuvant therapies that may be used to complement the antibody therapy such as IL-2 and IFN-γ cytokine therapy [59].

Last but not least, the rapid viral resistance developed from the bnAbs treatment is striking and has drawn considerable attention. This is mainly due to the high mutation rate of HIV-1. The resistance has been reported in various bnAbs targeting multiple sites including V1/V2, V3, and CD4 binding site. Bouvin-Phey et al. reported that HIV-1 clade B has increased resistance towards the bnAbs targeting gp120 as shown by VRC01, NIH45-46, PG9, PG16, PGT121, and PGT128 [99]. Interestingly, the same study has also shown that no increase of viral resistance was seen in bnAbs targeting MPER of gp41 such as 2F5 and 4E10 [99]. This could be due to the lack of selective pressure and/or a weak tolerance to mutations in this particular region [99]. Similarly, the viral resistance of bnAbs has also been predicted using several computational and mathematical models [100, 101]. To circumvent this issue, multispecific bnAbs and combination of bnAbs have been developed to concurrently target various epitopes of a protein to reduce the chances of viral resistance. This includes the recent development of a trispecific bnAbs targeting two CD4-binding sites and MPER [102], and a combination of two to four bnAbs targeting CD4-binding site, V1V2, V3, and MPER [103].

4. Future Perspectives and Conclusions

The abovementioned challenges must be looked into before the therapeutic antibodies are deemed suitable for clinical use. Development of technology and bioengineering such as advancement of antibody generation and isolation methods, improvement of target delivery, and specificity play important roles in improving the antiviral activities of therapeutic antibodies. Based on current literature, many studies demonstrated that antibody-mediated antiviral treatments have yet achieved complete inhibition against HIV-1. This may suggest that treatment using therapeutic antibodies may not be suitable to be used as a “standalone” therapy although extensive efforts are ongoing. This therapeutic modality may pose a higher value when used in combination with current anti-HIV therapies such as HAART or other antiviral small-molecule inhibitors. For example, it has been shown that the bnAb 3BNC117 when used in combination with HAART could enhance the host immune response against HIV-1 and leads to significant delay of viral rebound after treatment cessation [63, 104]. Although the combination treatment of small-molecule inhibitors and antiviral antibodies has not been studied, it is speculated that it will drastically improve the neutralizing potency of the HIV-1. This speculation, however, requires further investigations for validation. In addition to maximizing the neutralization efficacy, combination treatment targeting multiple sites of protein is also anticipated to significantly avert the selection of escape variants [97].

The discovery of bnAbs has also posed a significant impact on the development of anti-HIV vaccine. While bnAbs are able to tackle the extremely high diversity of HIV-1, it is understood that having a safe vaccine eliciting bnAbs could be an effective measure to control HIV spreading. However, there are no vaccination strategies by far to elicit the effective bnAbs responses [105]. Several attempts have been made to develop the vaccination strategy mainly using animal models. In both macaque and rabbit models, sequential vaccination with gp120 and gp40 proteins has shown improved potency of neutralization, respectively [106, 107]. Similarly, sequential vaccination with three gp120 variants also demonstrated potent neutralization [108]. To date, it remains unknown to elicit the bnAbs from the HIV patients through vaccination. The main challenges are the HIV-1
diversity and later on rapid viral resistance. Sequential vaccination with various immunogens with conserved regions may promote the B cell maturation and antibody responses.

Therapeutic antibodies are known as “magic bullets” due to the fact that they can treat various diseases and infections. A number of FDA-approved therapeutic antibodies in the current market highlight the potential of adopting antibodies for disease control. Broad neutralizing antibodies have demonstrated potent antiviral action against various strains of HIV-1 and a large number of them are currently being evaluated in the clinical trials. Continuous efforts are in progress to elucidate their potential use for anti-HIV treatment in clinics. Overcoming the abovementioned challenges will undoubtedly improve the application of therapeutic antibody to HIV/AIDS management in the future.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors participated in the literature search, interpretation of the articles reviewed, analysis of the data, and review of the manuscript. All authors have read and approved the paper.

Acknowledgments

The authors would like to acknowledge Sunway University Sunway Internal Research Grant 2018 (INT-2018-SHMS-SIHD-01) and National Cancer Council Malaysia (MAKNA) Cancer Research Award (CRA) 2016 (EXT-SIDS-SIHD-MAKNA-2017-01) for partly supporting this work. Noel Jacques Awu is a recipient of Sunway University Master’s Degree by Research Scholarship.

References


